國內首仿!科倫藥業(002422.SZ)枸櫞酸西地那非口崩片獲批
格隆匯4月29日丨科倫藥業(002422.SZ)公佈,公司的化學藥品“枸櫞酸西地那非口崩片”於近日獲得國家藥品監督管理局的藥品註冊批准。
西地那非為全球首個獲批用於治療勃起功能障礙的5型磷酸二酯酶選擇性抑制劑,具有起效迅速、療效確切等優勢,為勃起功能障礙國內臨牀應用最廣泛的一線用藥,2020年中國公立醫院和零售藥店共計銷售26.6億元。
枸櫞酸西地那非口崩片為輝瑞基於以患者為中心開發的西地那非迭代劑型,2019年在中國批准進口。口崩片無需飲水、口腔放置數秒即可崩解、最快12分鐘起效,可滿足該類患者對於服用方便、起效快、隱私性好的口服藥物的需求。在改善患者症狀的同時,提高性生活品質,為勃起功能障礙患者提供了安全、高效、方便的治療新體驗,帶來多維度獲益。
公吿稱,枸櫞酸西地那非口崩片為公司繼達泊西汀片和鹽酸伐地那非片後第三個獲批的男科治療藥物,為國內首仿獲批,將進一步提升公司在男科領域的管線競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.